MHRA adds boxed warnings to antidepressant leaflets as patient safety messaging expands
The MHRA is moving to strengthen how antidepressant risks are communicated to patients, with new safety measures aimed at two concerns that have persisted for years at the bedside: suicidal thoughts and behaviours, and sexual dysfunction that may continue after treatment stops. The change is not simply a rewording exercise. It is a redesign of how risk is presented at the point where patients first encounter the medicine, and again when they return for review or a dose change.
The updated measures include a new boxed warning in patient information leaflets, a patient card, and a supporting safety leaflet that will be rolled out in 2027. For some antidepressants, the term post-SSRI sexual dysfunction, or PSSD, will also be added to patient leaflets. The regulatory intent is plain: make the harms easier to see, easier to remember, and harder to miss when treatment decisions are being made in routine practice.
Suicidal thoughts during antidepressant treatment remain a highly sensitive issue because the risk can emerge early, especially after initiation or dose adjustment. The new guidance directs clinicians to discuss this with patients when starting treatment, changing the dose, or reviewing ongoing therapy, and to advise urgent medical attention if suicidal intent appears or worsens. For patients, the message is even more direct: do not wait if thoughts of self-harm intensify, and do not stop the medicine abruptly without speaking to a healthcare professional.
Sexual dysfunction carries a different kind of clinical weight. It is common enough to affect adherence, yet difficult enough for many patients to raise spontaneously. The MHRA’s decision to name PSSD in the leaflets for antidepressants associated with sexual dysfunction that may persist after discontinuation gives the syndrome formal regulatory visibility. In practice, that could change the timing and honesty of conversations before treatment starts, especially for patients who may accept transient side effects but would make different choices if they knew symptoms could outlast the drug itself.
Patient testimony and literature review drove the risk-minimisation overhaul
The regulatory action followed a detailed review convened after concerns from patients and families that current patient information leaflets were not communicating these risks adequately. A Commission on Human Medicines expert working group examined the effectiveness of existing risk-minimisation measures and met between May 2024 and July 2025. The findings were considered by the CHM in September 2025.
Patient and family experience sat at the center of that review. Families of some patients and individual patients described where the current warnings fall short and suggested practical improvements. The group also examined published literature since 2019, the last time the regulatory position on suicidal thoughts and behaviours, and sexual dysfunction that can persist after stopping treatment, was reviewed at committee level.
The most important clinical implication is that this is a communication intervention as much as a pharmacovigilance intervention. Antidepressant prescribing already depends on balancing symptom burden, suicide risk, tolerability, and the probability of benefit. When warning language is vague or buried, patients may leave the consultation without understanding the specific signs that should trigger urgent help. When it is explicit and repeated in multiple formats, the chance of earlier recognition rises.
A short line in the updated advice carries substantial weight in practice: some patients refer to the persistent sexual adverse effect as PSSD. Naming the problem does not solve it, but it helps clinicians recognize the symptom cluster, document it consistently, and respond to it as a legitimate treatment-related concern rather than a vague complaint.
New card, ancillary leaflet and broader system changes will shape prescribing conversations
The new boxed warning will appear in patient information leaflets, and a patient card will be available in digital form first, with a hard-copy version expected to be credit-card sized and easy to carry. Dispensers may provide the electronic card as an interim step before physical cards become available. The accompanying safety leaflet is still in development and will be distributed at the first consultation for new patients or the next consultation for existing patients once it launches in 2027.
The delay matters because it signals how much coordination is required across the health system. The MHRA is working with national partners on associated changes to guidance and reference materials, including possible updates to NICE guidance, the British National Formulary, and NHS advice, alongside work with the Royal Colleges of General Practice, Psychiatrists and Pharmacy. The goal is consistent messaging across prescribing, dispensing and follow-up care rather than isolated warnings that vary from one setting to another.
For clinicians, the practical task now is to embed the discussion into the first prescription and every dose change. Monitoring after initiation remains essential, particularly early in treatment when suicidal thoughts may emerge or worsen. For patients, the new materials are meant to do something straightforward but often neglected: make the warning visible before distress becomes a crisis. A leaflet, card and ancillary document cannot replace close review, but they can make the next conversation more informed.
Healthcare professionals are also being asked to report suspected adverse reactions through the Yellow Card scheme, including as much detail as possible about medical history, concomitant medicines, onset timing and treatment dates. That reporting pathway will remain important as the regulatory position evolves and the wider impact of the new wording is assessed in practice.
The central issue is not whether antidepressants should still be prescribed; they should, when indicated. The issue is whether patients are told, in language they can actually use, what to watch for and when to seek help. This update says the current answer has not been good enough, and it moves the safety conversation to the front of the prescribing encounter rather than the margins.